RWA Wealth Partners LLC Purchases 6,444 Shares of AstraZeneca PLC $AZN

RWA Wealth Partners LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 11.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,933 shares of the company’s stock after acquiring an additional 6,444 shares during the period. RWA Wealth Partners LLC’s holdings in AstraZeneca were worth $4,751,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. North Star Asset Management Inc. lifted its stake in AstraZeneca by 23.6% in the third quarter. North Star Asset Management Inc. now owns 5,314 shares of the company’s stock valued at $408,000 after buying an additional 1,014 shares during the period. TD Asset Management Inc grew its holdings in AstraZeneca by 20.0% in the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares during the period. Cozad Asset Management Inc. increased its stake in AstraZeneca by 1.5% in the third quarter. Cozad Asset Management Inc. now owns 12,953 shares of the company’s stock valued at $994,000 after purchasing an additional 194 shares in the last quarter. Parr Mcknight Wealth Management Group LLC raised its holdings in shares of AstraZeneca by 2.1% during the third quarter. Parr Mcknight Wealth Management Group LLC now owns 33,969 shares of the company’s stock valued at $2,606,000 after purchasing an additional 710 shares during the period. Finally, Compound Planning Inc. boosted its position in shares of AstraZeneca by 37.7% during the 3rd quarter. Compound Planning Inc. now owns 32,928 shares of the company’s stock worth $2,526,000 after purchasing an additional 9,014 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on AZN shares. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. HSBC reissued a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research note on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Trading Down 0.2%

Shares of AZN stock opened at $206.22 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The company has a market capitalization of $319.82 billion, a price-to-earnings ratio of 68.51, a PEG ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 52-week low of $122.48 and a 52-week high of $212.71. The company has a 50-day simple moving average of $131.31 and a two-hundred day simple moving average of $100.36.

AstraZeneca Announces Dividend

The firm also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be given a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s dividend payout ratio (DPR) is presently 74.83%.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.